Drugs / IFx-Hu2.0
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03655756 | Nov 2018 → Jul 2020 | cutaneous melanoma | TuHURA Biosciences, Inc. | Completed | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT06940440 | Oct 2025 → May 2026 overdue | cutaneous neuroendocrine carcinoma | TuHURA Biosciences, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT04925713 | Jun → Oct 2021 | skin basal cell carcinoma, skin squamous cell carcinoma | TuHURA Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04160065 | Mar 2020 → Oct 2023 | cutaneous neuroendocrine carcinoma, skin squamous cell carcinoma | TuHURA Biosciences, Inc. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06947928 | Dec 2025 → Mar 2027 expected | cutaneous neuroendocrine carcinoma | TuHURA Biosciences, Inc. | Recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT04853602 | — | cutaneous melanoma, cutaneous neuroendocrine carcinoma, skin squamous cell carcinoma | TuHURA Biosciences, Inc. | Available | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IFx-Hu2.0 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04853602 ↗ |
| Action | Activate | “Injection of IFx-Hu2.0 into the lesion facilitates the expression of the immunogenic Emm55 protein by the tumor cells.” NCT04925713 ↗ |
| Modality | Vaccine | “Therapeutic Cancer Vaccine” NCT03655756 ↗ |
| Route | Other | “Intratumoral injection of cutaneous, subcutaneous or nodal lesions” NCT03655756 ↗ |